PLAU and neoplasm: The molecule contains urokinase-type plasminogen activator (uPA) proteolytic cleavage sites at the junction of IL-15 and anti-PD1; thus, within the tumor microenvironment (often enriched with uPA), LH05 is cleaved, resulting in local release of the IL-15R agonist and remarkable antitumor immunity, even in cold tumors.